Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 15, 2005

View Archived Issues

Update on the antiarrhythmic properties of ZP-123

Novel orally active PI3Kgamma inhibitor effective in various models of inflammation

Dual HER1/HER2 inhibitor disclosed by BMS scientists

Hippocampal neurogenesis contributes to antidepressant action of SSR-125543A

In vivo studies show efficacy for LY-379268 in opiate relapse

Preliminary phase I data on GCS-100 in advanced solid tumors

BAL-8557 reported as effective as fluconazole in esophageal candidiasis

New data on the metabolic effects of SOM-230 in patients with acromegaly

Novel agents imparted for the treatment of obesity and lipoprotein disorders

Recent patents disclose therapeutic agents for gastrointestinal disorders

Alcon patents superoxide dismutase mimics for optic nerve and retinal damage

Phase Ib study investigates PXD-101 for advanced solid tumors

L-Lysine-D-amphetamine: Prodrug of D-amphetamine in clinical development

Biovitrum advances BVT-28949 into clinical testing for glaucoma

Novel glucagon inhibitor shows promise for type 2 diabetes

Arrow cleared to add U.S. sites to phase IIa study of A-60444 for RSV

Amarin reaches SPA agreement for phase III trials of Miraxion

Pharmacokinetics results for NRP-290 for pain

NIDA grant supports development of NicVAX

FDA removes clinical hold on PRTX-100

Vical grants options to Merck for cancer vaccines

Alvimopan enters phase III program for opioid-induced constipation

E1-I.N.T. studied in type 2 diabetes patients

Efficacy and potential impact of rotavirus vaccine explored

Study finds motavizumab safe, active in infants with respiratory syncytial virus

Arranon recommended for accelerated FDA approval

Sorafenib NDA granted priority review status

ODAC recommends approval of Revlimid

Dabigatran results encourage phase III investigation in atrial fibrillation patients

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026